JNCE News and Press, Jounce Therapeutics Inc. From 09/14/21

Gainers: BELLUS Health (NASDAQ:BLU) +26%, aTyr Pharma (NASDAQ:LIFE) +22%, Jounce Therapeutics (NASDAQ:JNCE) +14%, NanoViricides (NYSE:NNVC) +12%, Matinas BioPharma (NYSE:MTNB) +12%. Losers: Virpax Pharmaceuticals (NASDAQ:VRPX) -37%, RedHill Bi...

The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with this event. For further details see: Jounce Therapeutics (JNCE) Corporate Presentation

Jounce Therapeutics, Inc. (JNCE) Q2 2021 Earnings Conference Call August 05, 2021 08:00 A.M. ET Company Participants Mark Yore - Director of Corporate Development Richard Murray - CEO and President Elizabeth Trehu - CMO Dmitri Wiederschain - Chief Scientific Officer Kim Drapkin - CFO Conferen...

The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Jounce Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation

Image source: The Motley Fool. Jounce Therapeutics, inc (NASDAQ: JNCE) Q2 2021 Earnings Call Aug 5, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Jounce Therapeutics, inc (JNCE) Q2 2021 Earnings Call Transcript

Jounce Therapeutics (NASDAQ:JNCE): Q2 GAAP EPS of -$0.08 beats by $0.28. Revenue of $25.4M beats by $17.24M. As of June 30, 2021, cash, cash equivalents and investments were $246.1 million, compared to $213.2 million as of December 31, 2020. Press Release For further details see: ...

- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021- - Announced two additional LILRB family targets as potential future development candidates - - Ended the qu...

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2021 financial result...

Jounce is a clinical stage biotech company that is attempting to transform the treatment of cancer by developing novel immunotherapies. The science is promising, but still in its early stages. A license deal with Gilead has provided credibility to Jounce's platform and helped to s...

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wiederschain, Ph.D., Chief Scientific Office...